|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Shiraha H, Yamamoto K and Namba M: Human
hepatocyte carcinogenesis (review). Int J Oncol. 42:1133–1138.
2013.PubMed/NCBI
|
|
3
|
Perz JF, Armstrong GL, Farrington LA,
Hutin YJ and Bell BP: The contributions of hepatitis B virus and
hepatitis C virus infections to cirrhosis and primary liver cancer
worldwide. J Hepatol. 45:529–538. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yang Y, Nagano H, Ota H, et al: Patterns
and clinicopathologic features of extrahepatic recurrence of
hepatocellular carcinoma after curative resection. Surgery.
141:196–202. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hwang S, Moon DB and Lee SG: Liver
transplantation and conventional surgery for advanced
hepatocellular carcinoma. Transplant Int. 23:723–727. 2010.
View Article : Google Scholar
|
|
6
|
Abdel-Wahab M, Sultan AM, Fathy OM, et al:
Factors affecting recurrence and survival after living donor liver
transplantation for hepatocellular carcinoma.
Hepatogastroenterology. 60:1847–1853. 2013.PubMed/NCBI
|
|
7
|
Sandhu DS, Baichoo E and Roberts LR:
Fibroblast growth factor signaling in liver carcinogenesis.
Hepatology. 59:1166–1173. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Guégan JP, Ezan F, Théret N, Langouët S
and Baffet G: MAPK signaling in cisplatin-induced death:
predominant role of ERK1 over ERK2 in human hepatocellular
carcinoma cells. Carcinogenesis. 34:38–47. 2013.PubMed/NCBI
|
|
9
|
Fuchs BC, Hoshida Y, Fujii T, et al:
Epidermal growth factor receptor inhibition attenuates liver
fibrosis and development of hepatocellular carcinoma. Hepatology.
59:1577–1590. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gao W, Kim H, Feng M, et al: Inactivation
of Wnt signaling by a human antibody that recognizes the heparan
sulfate chains of glypican-3 for liver cancer therapy. Hepatology.
60:576–587. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dhillon AS, Hagan S, Rath O and Kolch W:
MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim EK and Choi EJ: Pathological roles of
MAPK signaling pathways in human diseases. Biochim Biophys Acta.
1802:396–405. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jeong DG, Wei CH, Ku B, et al: The
family-wide structure and function of human dual-specificity
protein phosphatases. Acta Crystallogr D Biol Crystallogr.
70:421–435. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu GS: Role of mitogen-activated protein
kinase phosphatases (MKPs) in cancer. Cancer Metastasis Rev.
26:579–585. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Keyse SM: Dual-specificity MAP kinase
phosphatases (MKPs) and cancer. Cancer Metastasis Rev. 27:253–261.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Haagenson KK and Wu GS: Mitogen activated
protein kinase phosphatases and cancer. Cancer Biol Ther.
9:337–340. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Haagenson KK and Wu GS: The role of MAP
kinases and MAP kinase phosphatase-1 in resistance to breast cancer
treatment. Cancer Metastasis Rev. 29:143–149. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sekine Y, Tsuji S, Ikeda O, et al:
Regulation of STAT3-mediated signaling by LMW-DSP2. Oncogene.
25:5801–5806. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sekine Y, Ikeda O, Hayakawa Y, et al:
DUSP22/LMW-DSP2 regulates estrogen receptor-alpha-mediated
signaling through dephosphorylation of Ser-118. Oncogene.
26:6038–6049. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li JP, Fu YN, Chen YR and Tan TH: JNK
pathway-associated phosphatase dephosphorylates focal adhesion
kinase and suppresses cell migration. J Biol Chem. 285:5472–5478.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rahmouni S, Cerignoli F, Alonso A, et al:
Loss of the VHR dual-specific phosphatase causes cell-cycle arrest
and senescence. Nat Cell Biol. 8:524–531. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shang X, Vasudevan SA, Yu Y, et al:
Dual-specificity phosphatase 26 is a novel p53 phosphatase and
inhibits p53 tumor suppressor functions in human neuroblastoma.
Oncogene. 29:4938–4946. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Klinger S, Poussin C, Debril MB, Dolci W,
Halban PA and Thorens B: Increasing GLP-1-induced beta-cell
proliferation by silencing the negative regulators of signaling
cAMP response element modulator-alpha and DUSP14. Diabetes.
57:584–593. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Patterson KI, Brummer T, O’Brien PM and
Daly RJ: Dual-specificity phosphatases: critical regulators with
diverse cellular targets. Biochem J. 418:475–489. 2009.PubMed/NCBI
|
|
25
|
Prabhakar S, Asuthkar S, Lee W, et al:
Targeting DUSPs in glioblastomas - wielding a double-edged sword?
Cell Biol Int. 38:145–153. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nunes-Xavier C, Romá-Mateo C, Ríos P, et
al: Dual-specificity MAP kinase phosphatases as targets of cancer
treatment. Anticancer Agents Med Chem. 11:109–132. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ríos P, Nunes-Xavier CE, Tabernero L, Köhn
M and Pulido R: Dual-specificity phosphatases as molecular targets
for inhibition in human disease. Antioxid Redox Signal.
20:2251–2273. 2014.PubMed/NCBI
|
|
28
|
Thornton TM and Rincon M: Non-classical
p38 map kinase functions: cell cycle checkpoints and survival. Int
J Biol Sci. 5:44–51. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wagner EF and Nebreda AR: Signal
integration by JNK and p38 MAPK pathways in cancer development. Nat
Rev Cancer. 9:537–549. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ayub A, Ashfaq UA and Haque A: HBV induced
HCC: major risk factors from genetic to molecular level. Biomed Res
Int. 2013:8104612013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Arnoldussen YJ, Lorenzo PI, Pretorius ME,
et al: The mitogen-activated protein kinase phosphatase vaccinia
H1-related protein inhibits apoptosis in prostate cancer cells and
is overexpressed in prostate cancer. Cancer Res. 68:9255–9264.
2008. View Article : Google Scholar
|
|
32
|
Henkens R, Delvenne P, Arafa M, et al:
Cervix carcinoma is associated with an up-regulation and nuclear
localization of the dual-specificity protein phosphatase VHR. BMC
cancer. 8:1472008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tang JP, Tan CP, Li J, et al: VHZ is a
novel centrosomal phosphatase associated with cell growth and human
primary cancers. Mol Cancer. 9:1282010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Deng Q, Li KY, Chen H, et al: RNA
interference against cancer/testis genes identifies dual
specificity phosphatase 21 as a potential therapeutic target in
human hepatocellular carcinoma. Hepatology. 59:518–530. 2014.
View Article : Google Scholar
|
|
35
|
Bai L, Yoon SO, King PD and Merchant JL:
ZBP-89-induced apoptosis is p53-independent and requires JNK. Cell
Death Differ. 11:663–673. 2004.PubMed/NCBI
|
|
36
|
Yu W, Imoto I, Inoue J, Onda M, Emi M and
Inazawa J: A novel amplification target, DUSP26, promotes
anaplastic thyroid cancer cell growth by inhibiting p38 MAPK
activity. Oncogene. 26:1178–1187. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bertoli C, Skotheim JM and de Bruin RA:
Control of cell cycle transcription during G1 and S phases. Nat Rev
Mol Cell Biol. 14:518–528. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hui L, Bakiri L, Mairhorfer A, et al:
p38alpha suppresses normal and cancer cell proliferation by
antagonizing the JNK-c-Jun pathway. Nat Genet. 39:741–749. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hui L, Bakiri L, Stepniak E and Wagner EF:
p38alpha: a suppressor of cell proliferation and tumorigenesis.
Cell Cycle. 6:2429–2433. 2007. View Article : Google Scholar : PubMed/NCBI
|
